

Mid-Way Point Reached in Landmark Alzheimer's Trial - XanADu

- Major milestone achieved with a total of 87 patients enrolled into XanADu - representing half of the total patients required to complete the trial
- Trial progressing on schedule and expected to enrol the final patient in Q4 2018 with top-line results in Q2 2019
- Interim analysis of XanADu to commence in Q2 2018 once the 50th evaluable patient completes the trial

Sydney, 21 March 2018: Actinogen Medical (ASX: ACW) is pleased to announce it has reached the mid-way point in patient enrolment for its landmark Phase II clinical trial (XanADu) of Xanamem in the treatment of Alzheimer's disease.

A total of 87 patients have been enrolled into XanADu, representing half of the total 174 patients planned for the study. The trial continues to enrol on target, with the final patient expected in the fourth quarter of this calendar year, and the top-line results by April/May 2019. Importantly, XanADu is fully funded through to the end of the trial.

Dr Robert A. Riesenber MD, Principal Investigator (PI) of the Atlanta Center for Medical Research (ACMR), one of the largest and most respected clinical research institutions in the USA and one of XanADu's leading patient recruitment sites commented, "We're excited about the potential for Xanamem in Alzheimer's disease, particularly as it's not targeting amyloid. So many amyloid-related drugs under development have seen unfavourable outcomes in recent years, so it's particularly encouraging, for us and our patients, to be trialling a drug with a novel mechanism of action".

Additionally, as announced previously, the Data Safety and Monitoring Board (DSMB) will commence an Interim Analysis of XanADu once the 50th evaluable patient has completed the 12-week treatment period and 4-week follow up phase. The output from the DSMB analysis is expected to be available in late May or early June this year.

"Our XanADu trial is ground-breaking in the field of Alzheimer's drug development and it places the Company at the forefront of Alzheimer's disease research." commented Dr Bill Ketelbey, CEO of Actinogen Medical. "We're delighted to have reached the half way point on schedule and we look forward to completing patient enrolment later this year. We also keenly await the commencement of the interim analysis and to sharing the output from the DSMB in late May or June", he continued.

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au

Media Enquires

Zena Chamas
Media & Capital Partners
M: +61 434 153 055
E: zena.chamas@mcpartners.com.au

 @BillKetelbey

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.